Michael Vi/iStock Editorial via Getty Images
Developers of a drug class called anti-TIGIT immunotherapies traded higher in pre-market trading on Wednesday after Roche (OTCQX:RHHBY) accidentally released interim data from its SKYSCRAPER-01 study.
The global trial was designed to evaluate Roche’s (OTCQX:RHHBF) TIGIT-targeting immune checkpoint inhibitor tiragolumab in combination with its PD-L1 inhibitor Tecentriq as a first-line option for certain patients with non-small cell lung cancer.
According to mistakenly shared data from its second interim analysis, the patients on the experimental therapy indicated a 0.81 hazard ratio, meaning those on tiragolumab and Tecentriq demonstrated a 19% lower probability of death when compared to those on Tecentriq alone.
The interim readout based on a data cut in November 2022 further indicates a median overall survival of 22.9 months for the tiragolumab plus Tecentriq arm compared to 16.7 months in the Tecentriq-only arm.
However, data on overall survival, the primary goal of SKYSCRAPER-01, were not mature at the time of the analysis, Roche (OTCQX:RHHBF) unit, Genentech, said, adding that the analysis took place in February when the median follow-up was 15.5 months.
The drug combination was well tolerated without any new safety signals.
Roche’s (OTCQX:RHHBY) rivals in the anti-TIGIT space, Arcus Biosciences (RCUS), iTeos Therapeutics (ITOS), Compugen (CGEN), and Mereo BioPharma (MREO) traded higher in reaction to data.
